Vincent Vultaggio
Chief Accounting Officer
Zentalis Pharmaceuticals, Inc. (ZNTL)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Vincent Vultaggio
Vincent Vultaggio is recorded as CFO and Chief Accounting Officer at Zentalis Pharmaceuticals, Inc. (ZNTL). Zentalis Pharmaceuticals, Inc. reported in an 8-K filed November 13, 2024 that Vincent Vultaggio was appointed interim principal financial officer, effective November 13, 2024. Zentalis Pharmaceuticals, Inc. reported in an 8-K filed April 11, 2024 that Vincent Vultaggio was appointed interim principal accounting officer, effective April 5, 2024.
“On November 12, 2024, the Board designated Vincent Vultaggio, the Company's Senior Vice President, Finance and Principal Accounting Officer, as principal financial officer on an interim basis, effective on the Transition Date.”
“Effective on the Transition Date, the Company’s Board of Directors (the “Board”) appointed the Company’s President, Cam Gallagher, as interim Chief Financial Officer, Treasurer and principal financial officer, and the Company’s Vice President, Finance, Vincent Vultaggio, as interim principal accounting officer.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2024-11-13–present
-
Current
2024-04-05–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Zentalis Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- Julie Eastland CEO, Board Member
- Kimberly Blackwell, M.D. CEO
- David M. Johnson Chairman
- Scott Myers Chairman, Board Member
- Cam Gallagher CFO
- Iris Roth COO
- Iris Roth, Ph.D. COO
- James B. Bucher General Counsel
- David Johnson Board Member
- Enoch Kariuki Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.